Baseline in vitro parameters of GC sensitivity in healthy controls, tREACH, and FLARE patients. The IL-2 assay (A) and GILZ-assay (C) were performed in both tREACH and FLARE patients (bioassays in 32 patients, GC-binding assay in 32 patients, bioassays and GC-binding assay in 27 patients; control groups for the bioassays (n = 20) and binding assay (n = 16) were not the same). As secondary outcome, IL-2 repression (B) and GILZ induction (D) was calculated as follows: The numbers of GRs (E) and the affinity of the receptor (F) were determined in FLARE patients only. EC50, half maximal effective concentration. P values were calculated by using ANOVA and Bonferroni post hoc correction; normalized data were used where appropriate.
Quax et al. Arthritis Research & Therapy 2012 14:R195 doi:10.1186/ar4029